This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wells Fargo Sticks to Their Hold Rating for Molina Healthcare (MOH)

Tipranks - Tipranks - Fri Jun 5, 8:28PM CDT

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Molina Healthcare, with a price target of $159.00.

Claim 55% Off TipRanks

According to TipRanks, Baxter is a 3-star analyst with an average return of 1.6% and a 47.08% success rate. Baxter covers the Healthcare sector, focusing on stocks such as Cencora, Elevance Health, and CVS Health.

In addition to Wells Fargo, Molina Healthcare also received a Hold from Morgan Stanley’s Erin Wright in a report issued yesterday. However, on May 27, Bernstein maintained a Buy rating on Molina Healthcare (NYSE: MOH).

See the top stocks recommended by analysts >>

Based on Molina Healthcare’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10.8 billion and a net profit of $14 million. In comparison, last year the company earned a revenue of $11.15 billion and had a net profit of $298 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Last month, Maurice Hebert, the CAO of MOH sold 600.00 shares for a total of $114,930.00.

Read More on MOH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).